Delayed reactions to contrast media after interleukin-2 immunotherapy.
A prospective study was conducted by means of a questionnaire to determine the prevalence of delayed reactions to contrast media administered intravenously (iopamidol) and orally (diatrizoate sodium) in 170 patients who had received interleukin-2 (IL-2) and in 631 patients who did not. Another control group of 100 non-IL-2 patients received only oral contrast medium. Delayed reactions (eg, fever rash, flulike symptoms, joint pain, flushing, pruritus, and dizziness) were reported in 3.9% (25 of 631) of non-IL-2 patients and in 11.8% (20 of 170) of IL-2 patients. Reactions were mild in the non-IL-2 patients but were more severe in the IL-2 patients. Two IL-2 patients required hospitalization. Only rash, flulike symptoms, and pruritus were statistically more common in IL-2 patients than in non-IL-2 patients. The prevalence of delayed reactions to nonionic contrast medium is higher in patients who have received IL-2 than in the general population. Most delayed reactions do not require therapy, but, when necessary, therapy is usually limited to relief of symptoms.
Choyke
P L
PL
Diagnostic Radiology Department, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Miller
D L
DL
Lotze
M T
MT
Whiteis
J M
JM
Ebbitt
B
B
Rosenberg
S A
SA
D000284:Administration, Oral; D003973:Diatrizoate / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007167:Immunotherapy; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000627:therapeutic use*; D007479:Iopamidol / Q000008:administration & dosage / Q000009:adverse effects*; D011446:Prospective Studies; D013997:Time Factors
D007376:Interleukin-2; D003973:Diatrizoate; D007479:Iopamidol